|
|
Sun Pharmaceuticals Industries (HDFC Securities) Q1FY12 Result Update |
|
Sun Pharmaceuticals Industries (ICICI securities) Upside well captured |
|
Taro profits up 118% YoY | Date | Rating | Target Price | Recommendation Price | Broker house | | 1 Aug 2011 | hold | 495 (from 491) | 518 | ICICI securities Report | |
|
Sun Pharmaceuticals Industries (Goldman Sachs) In line with expectations: Maintain 24% sales growth for FY12E; Sell |
| Date | Rating | Target Price | Recommendation Price | Broker house | | 1 Aug 2011 | sell | 327 | 518 | Goldman Sachs Report | |
|
Sun Pharmaceuticals Industries (Angel) Better-than-expected results |
| Date | Rating | Target Price | Recommendation Price | Broker house | | 30 Jul 2011 | neutral | -- | 517 | Angel Report | |
|
Sun Pharmaceuticals Industries (Citi) 1Q: Healthy Quarter |
|
Good numbers;Strong revenue growth;EBITDA margin, net income surprised;Taro integration: good start | Date | Rating | Target Price | Recommendation Price | Broker house | | 29 Jul 2011 | hold | 525 | 523 | Citi Report | |
|
Sun Pharmaceuticals Industries (Emkay) Going Strong; Maintain Hold |
|
Result Highlights;Future growth drivers | Date | Rating | Target Price | Recommendation Price | Broker house | | 29 Jul 2011 | hold | 519 | 517 | Emkay Report | |
|
Sun Pharmaceuticals Industries (Sharekhan) Price target revised to Rs575 |
|
Ugly Duckling
Earnings ahead of Street estimates
Performance by geography
Operating margins contracted by 11 percentage points YoY but improved QoQ:
Healthy other income through receipt of interest | Date | Rating | Target Price | Recommendation Price | Broker house | | 29 Jul 2011 | buy | 575 (from ??) | 517 | Sharekhan Report | |
|
Sun Pharmaceuticals Industries (Deutsche Bank) Momentum at US sub. -Taro- continues with robust 2QCY11 |
|
Robust quarterlies of Taro continue;but may come under pressure | Date | Rating | Target Price | Recommendation Price | Broker house | | 28 Jul 2011 | hold | 450 | 517 | Deutsche Bank Report | |
|
Sun Pharmaceuticals Industries (Sharekhan) Q1FY2012 results: First-cut analysis |
|
Ugly Duckling
Earnings ahead of Street estimates
Performance by geography
Operating margins contracted by 11 percentage points YoY but improved QoQ
Healthy other income through receipt of interest | Date | Rating | Target Price | Recommendation Price | Broker house | | 28 Jul 2011 | buy | 534 | 518 | Sharekhan Report | |
|
Sun Pharmaceuticals Industries (Deutsche Bank) 5+ companies share exclusivity for alfuzosin -Uroxatral |
|
Yesterday, Sun Pharma announced approval for alfuzosin -branded Uroxatral;Limited upsides | Date | Rating | Target Price | Recommendation Price | Broker house | | 21 Jul 2011 | hold | 450 | 501 | Deutsche Bank Report | |
|
|
|
|
Page 1 of 9 |
